Losartan

Generic Name: Losartan

Brand Names: Hyzaar, Cozaar

Drug Type: Small Molecule

Chemical Formula: C_₂₂H_₂₃ClN_₆O

CAS Number: 114798-26-4

Unique Ingredient Identifier: JMS50MPO89

Background: Losartan is an angiotensin II receptor blocker (ARB) used to treat hypertension. Angiotensin-converting enzyme (ACE) inhibitors are used for a similar indication but are associated with a cough. When patients with ACE inhibitor associated coughs are switched to ARBs like losartan, they have an incidence of cough similar to placebo or hydrochlorothiazide. Los...

Indication: Losartan is indicated to treat hypertension in patients older than 6 years, reduce the risk of stroke in patients with hypertension and left ventricular hypertrophy (though this benefit may not extend to patients with African heritage), and to treat diabetic nephropathy with elevated serum creatinine and proteinuria in patients with type 2 diabetes and hyper...

Associated Conditions: Diabetic Nephropathy, Ventricular Dysfunction, Hypertension, Marfan Syndrome, Ischemic Stroke

Associated Therapies: -

Clinical Trials

Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients

Phase 4

Conditions: End Stage Renal Disease
Peritoneal Dialysis

Interventions: Drug: Spironolactone
Drug: Losartan

First Posted Date: 2019-05-17

Last Posted Date: 2019-09-04

Lead Sponsor: Chiang Mai University

Target Recruit Count: 84

Registration Number: NCT03953950

Locations: 🇹🇭
Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand

Imaging Perfusion Restrictions From Extracellular Solid Stress - An Open-label Losartan Study

Phase 2

Conditions: Glioblastoma
Brain Metastases

Interventions: Drug: Losartan

First Posted Date: 2019-05-15

Last Posted Date: 2023-11-01

Lead Sponsor: Kyrre Eeg Emblem

Target Recruit Count: 165

Registration Number: NCT03951142

Locations: 🇳🇴
Oslo University Hospital, Oslo, Norway

The Pharmacokinetic Interaction Between Amlodipine and Losartan

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Amlodipine10mg
Drug: Losartan potassium 100mg
Drug: Amlodipine plus Losartan

First Posted Date: 2019-04-11

Last Posted Date: 2019-04-12

Lead Sponsor: Korea University Anam Hospital

Target Recruit Count: 24

Registration Number: NCT03912285

Locations: 🇰🇷
Dept. of Clinical Pharmacology & Toxicology, Anam Hospital, Korea University College of Medicine, Seoul, Korea, Republic of

Losartan + Sunitinib in Treatment of Osteosarcoma

Phase 1

Recruiting

Conditions: Osteosarcoma

Interventions: Drug: Losartan
Drug: Sunitinib

First Posted Date: 2019-04-03

Last Posted Date: 2024-12-20

Lead Sponsor: University of Colorado, Denver

Target Recruit Count: 41

Registration Number: NCT03900793

Locations: 🇺🇸
Children's Hospital Colorado, Aurora, Colorado, United States
🇺🇸
University of Colorado Hospital, Aurora, Colorado, United States
🇺🇸
Children's Hospital of Atlanta, Atlanta, Georgia, United States

A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension

Phase 2

Completed

Conditions: Hypertension

Interventions: Drug: HCP1803
Drug: Amlodipine
Drug: Losartan
Drug: Placebo

First Posted Date: 2019-04-01

Last Posted Date: 2022-07-14

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 248

Registration Number: NCT03897868

Locations: 🇰🇷
Donggguk University Ilsan Hospital, Goyang-si, Gyeonggi-do, Korea, Republic of

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

Phase 1

Terminated

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Anatomic Stage IV Breast Cancer AJCC v8
Anemia
Ann Arbor Stage III Hodgkin Lymphoma
Ann Arbor Stage III Non-Hodgkin Lymphoma
Ann Arbor Stage IV Hodgkin Lymphoma
Ann Arbor Stage IV Non-Hodgkin Lymphoma
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Castration-Resistant Prostate Carcinoma

Interventions: Drug: Abemaciclib
Drug: Abiraterone
Drug: Afatinib
Biological: Bevacizumab
Drug: Bicalutamide
Procedure: Biospecimen Collection
Drug: Bortezomib
Drug: Cabazitaxel
Drug: Cabozantinib
Drug: Capecitabine
Drug: Carboplatin
Drug: Celecoxib
Drug: Cobimetinib
Drug: Copanlisib
Drug: Dabrafenib
Drug: Dacomitinib
Drug: Darolutamide
Drug: Dasatinib
Drug: Doxorubicin
Biological: Durvalumab
Drug: Enasidenib
Drug: Entrectinib
Drug: Enzalutamide
Drug: Erlotinib
Drug: Everolimus
Drug: Fluorouracil
Drug: Idelalisib
Drug: Imatinib
Biological: Ipilimumab
Drug: Lenvatinib
Drug: Leucovorin
Drug: Lorlatinib
Drug: Losartan
Drug: Nab-paclitaxel
Drug: Neratinib
Biological: Nivolumab
Drug: Olaparib
Drug: Oxaliplatin
Drug: Palbociclib
Drug: Panobinostat
Biological: Pembrolizumab
Biological: Pertuzumab
Drug: Ponatinib
Other: Quality-of-Life Assessment
Drug: Regorafenib
Drug: Ruxolitinib
Drug: Sirolimus
Drug: Sorafenib
Drug: Sunitinib
Drug: Trametinib
Biological: Trastuzumab Emtansine
Drug: Tretinoin
Drug: Vemurafenib
Drug: Venetoclax
Drug: Vismodegib
Drug: Vorinostat

First Posted Date: 2019-03-18

Last Posted Date: 2024-03-04

Lead Sponsor: OHSU Knight Cancer Institute

Target Recruit Count: 2

Registration Number: NCT03878524

Locations: 🇺🇸
OHSU Knight Cancer Institute, Portland, Oregon, United States

Pharmacokinetic Drug-drug Interaction Study of Encorafenib and Binimetinib on Probe Drugs in Patients With BRAF V600-mutant Melanoma or Other Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Metastatic Melanoma
Advanced Solid Tumors

Interventions: Drug: losartan
Drug: rosuvastatin
Drug: bupropion immediate release (IR)
Drug: dextromethorphan
Drug: caffeine
Drug: modafinil
Drug: omeprazole
Drug: midazolam
Drug: encorafenib
Drug: binimetinib

First Posted Date: 2019-03-06

Last Posted Date: 2023-06-08

Lead Sponsor: Pfizer

Target Recruit Count: 56

Registration Number: NCT03864042

Locations: 🇨🇦
Sir Mortimer B Davis Jewish General Hospital, Montreal, Quebec, Canada
🇺🇸
UC Irvine Health, Orange, California, United States
🇺🇸
University of Colorado Hospital - Anschutz Cancer Pavilion (ACP), Aurora, Colorado, United States

and more 26 locations

Losartan and Emotional Memory

Not Applicable

Completed

Conditions: Memory
Learning

Interventions: Other: placebo
Drug: Losartan Potassium

First Posted Date: 2018-12-04

Last Posted Date: 2018-12-06

Lead Sponsor: University of Oxford

Target Recruit Count: 53

Registration Number: NCT03763409

Locations: 🇬🇧
Department of Psychiatry, University of Oxford, Oxford, United Kingdom

Nighttime Losartan in Continous Ambulatory Peritoneal Dialysis (NVCAPD)

Phase 4

Conditions: Hypertension,Nephropathy

Interventions: Drug: Losartan

First Posted Date: 2018-10-02

Last Posted Date: 2018-11-05

Lead Sponsor: Fifth Affiliated Hospital, Sun Yat-Sen University

Target Recruit Count: 68

Registration Number: NCT03692013

Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease

Phase 4

Completed

Conditions: Aortic Stenosis
Aortic Regurgitation
Hypertension
LVM
Left Ventricular Hypertrophy

Interventions: Drug: Amlodipine 5mg
Drug: Losartan
Drug: Losartan and Amlodipine
Drug: Amlodipine/Losartan/Chlorthalidone
Drug: current treatment

First Posted Date: 2018-09-11

Last Posted Date: 2022-09-15

Lead Sponsor: Hanmi Pharmaceutical Company Limited

Target Recruit Count: 128

Registration Number: NCT03666351

Locations: 🇰🇷
10 Institutions Including Asan Medical Center, Seoul, Korea, Republic of

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy